Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $44.35M
• Dividend Yield: N/A
• Average Volume (3M): 38.26K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.75
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.66
• Shares Outstanding: 10,250,588
• 10 Day Avg. Volume: 55,320
• 30 Day Avg. Volume: 38,262
• PEG Ratio: <0.01
• Price to Book (P/B): 57.52
• Price to Sales (P/S): 658.37
• P/FCF Ratio: -2.15
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 467.15
• Enterprise Value/Gross Profit: 30.36K
• Enterprise Value/Ebitda: -4.87
• 1Y Price Target: $13.00
• Price Target Upside: 232.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $4.00 ▲(2.30% Upside)

The overall stock score for Serina Therapeutics is primarily driven by its poor financial performance, which is the most significant factor. The technical analysis also indicates bearish trends, further contributing to the low score. The valuation metrics reflect high risk due to negative profitability. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Innovative Drug Delivery Systems

The company's focus on innovative drug delivery systems provides a competitive advantage by enhancing the efficacy and safety of therapies, potentially leading to strong partnerships and revenue growth.

Strategic Partnerships

Strategic partnerships with pharmaceutical companies provide a stable revenue stream and opportunities for growth through collaborative drug development, leveraging Serina's proprietary technologies.

Focus on Unmet Medical Needs

Targeting unmet medical needs positions Serina Therapeutics in high-demand markets, potentially driving long-term growth as it addresses critical gaps in treatment options.

Negative Factors

High Liabilities

High liabilities and negative equity indicate financial instability, which could hinder the company's ability to invest in R&D and sustain operations without restructuring.

Negative Cash Flow

Negative cash flow from operations suggests difficulties in sustaining business activities, potentially requiring external funding and impacting long-term viability.

Declining Revenue

Declining revenue and negative profit margins highlight operational inefficiencies and market challenges, threatening the company's ability to achieve profitability.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

How the Company Makes Money

Serina Therapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies that seek to utilize its proprietary drug delivery technologies. The company may also earn income from licensing agreements for its developed products, as well as potential milestone payments and royalties from partnered drug development programs. Additionally, government grants and funding for research projects may contribute to the company's financial resources, allowing it to advance its product pipeline and expand its therapeutic offerings.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	130.00K	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	2.00K	-138.00K	3.06M	355.00K	-110.00K	-1.23M
EBITDA	-12.47M	-10.49M	5.92M	-7.05M	-7.35M	-8.74M
Net Income	-12.59M	-11.14M	5.27M	-2.68M	-1.26M	-10.87M
Balance Sheet
Total Assets	8.94M	6.72M	11.96M	858.04K	1.84M	3.92M
Cash, Cash Equivalents and Short-Term Investments	6.04M	3.67M	7.62M	532.23K	1.31M	527.00K
Total Debt	185.00K	268.00K	4.37M	1.81M	398.17K	6.30M
Total Liabilities	7.29M	6.22M	6.61M	38.64M	36.95M	9.32M
Stockholders Equity	1.80M	641.00K	5.47M	-17.21M	-11.83M	-5.12M
Cash Flow
Free Cash Flow	-15.63M	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-15.62M	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-54.00K	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	15.60M	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.91
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Negative. The current price of 3.91 is below the 20-day moving average (MA) of 4.82, below the 50-day MA of 5.02, and below the 200-day MA of 5.24, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 29.14 is Positive, neither overbought nor oversold. The STOCH value of 12.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRNS	43 Neutral	$48.01M	―	-53.78%	―	―	-5.42%
SER	39 Underperform	$44.35M	-0.73	―	―	―	―
SKYE	38 Underperform	$47.41M	―	-72.75%	―	―	72.65%
CELU	38 Underperform	$45.91M	-0.54	-6367.24%	―	4.45%	45.19%
OTLK	38 Underperform	$52.86M	―	―	―	―	86.28%

Serina Therapeutics Corporate Events

Serina Therapeutics Secures $5M for Parkinson’s Trial

On October 6, 2025, Serina Therapeutics announced the receipt of the first $5 million funding tranche from a $20 million financing agreement to support the registrational trial of SER-252 for advanced Parkinson’s disease. The company has submitted an IND to the FDA and received HREC approval in Australia, with the trial set to begin in Q4 2025, marking a significant step in addressing unmet needs for Parkinson’s patients.

The most recent analyst rating on (SER) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Serina Therapeutics Secures $20M Convertible Note Agreement

On September 9, 2025, Serina Therapeutics entered into a $20 million unsecured convertible note agreement with board member Gregory H. Bailey, M.D. The funding, structured in five tranches, is tied to clinical and operational milestones, supporting the company’s SER-252-1b clinical study. This financial arrangement strengthens Serina’s operational capabilities and positions it strategically within the biotechnology sector. The agreement includes provisions for interest, conversion into common stock, and issuance of warrants, reflecting a significant step in the company’s growth and development plans.

The most recent analyst rating on (SER) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Serina Therapeutics Secures $20M for Parkinson’s Trial

On September 9, 2025, Serina Therapeutics announced securing up to $20 million in financing to advance the registrational trial of SER-252 for Parkinson’s disease. This funding, led by Board Director Greg Bailey, MD, will support the Phase 1b clinical study under the 505(b)(2) NDA pathway. The financing structure allows flexibility in capital deployment and includes potential additional proceeds through warrant issuance. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of SER-252, a novel apomorphine therapy designed for continuous dopaminergic stimulation in advanced Parkinson’s patients. The study will be conducted in the U.S. and Australia, with key milestones anticipated in 2025 and 2026.

The most recent analyst rating on (SER) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Serina Therapeutics Amends Bylaws for Governance Transparency

On August 18, 2025, Serina Therapeutics‘ Board of Directors amended the company’s bylaws to introduce safe harbor procedures for transactions involving directors, officers, and controlling stockholders with potential conflicts of interest. Additionally, the amendment expanded the forum selection clause to cover stockholder claims related to the corporation’s business, conduct, or rights, potentially impacting how legal disputes are managed and enhancing corporate governance transparency.

The most recent analyst rating on (SER) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.